An FDA-cleared AI tool for breast ultrasound may reduce unnecessary biopsies of benign breast lesions by about 60%.
Key Details
- 1Research presented at RSNA 2025 evaluated the Koios DS AI tool for breast ultrasound.
- 2The study involved 14 breast imaging radiologists and 271 lesions in 253 women, with 76.8% benign and 23.2% malignant lesions.
- 3The AI tool showed 60.6% specificity, assigning many benign lesions to lower BI-RADS categories, and a sensitivity of 90.5%.
- 4The tool misclassified 6 malignant lesions, most of which had other imaging correlates.
- 5Experts emphasized the AI should be used as an adjunct, not a replacement, to radiologist judgment for biopsy decisions.
Why It Matters
Reducing unnecessary biopsies can lower patient anxiety, cut healthcare costs, and ease operational burdens on imaging practices. Integrating AI as a decision-support tool alongside radiologists could lead to more accurate, efficient, and patient-centered breast imaging workflows.
Source
AuntMinnie
Related News
•Radiology Business
FDA Clears Multi-Disease AI Screening Platform for CT Imaging
HeartLung Corporation's AI-CVD platform receives FDA clearance to detect multiple diseases from a single CT scan.
•Cardiovascular Business
FDA Expands Clearance for AI-Guided Echo Exams on Existing Ultrasound Systems
FDA clears UltraSight's AI platform for use with a broader range of existing ultrasound devices, aiding novice users in performing echocardiographic exams.
•Radiology Business
a2z Radiology Raises $5M, Lands FDA Clearance for Multi-Condition CT AI
Boston-based a2z Radiology raised $4.5M and earned FDA clearance for its Unified Triage AI solution for abdominal and pelvic CT scans.